Drug Type Biosimilar, Monoclonal antibody |
Synonyms CetuGEX, Cetuximab biobetter, GT-MAB 5.2-GEX + [2] |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Squamous Cell Carcinoma of Head and Neck | Phase 2 | BE | 01 Feb 2014 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | FR | 01 Feb 2014 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | DE | 01 Feb 2014 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | IT | 01 Feb 2014 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | PL | 01 Feb 2014 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | RO | 01 Feb 2014 | |
Squamous Cell Carcinoma of Head and Neck | Phase 2 | ES | 01 Feb 2014 | |
EGFR mutation Solid Tumors | Phase 1 | DE | 02 Nov 2017 | |
EGFR mutation Solid Tumors | Phase 1 | IT | 02 Nov 2017 | |
EGFR mutation Solid Tumors | Phase 1 | ES | 02 Nov 2017 |
Phase 1 | 52 | (primary phase) | bvoohhxpty(yhuiplwidb) = hjcidawbdh cudizlcbxd (szukvnlndx ) View more | Positive | 20 May 2021 | ||
(expansion phase) | bvoohhxpty(yhuiplwidb) = idkbkrhezm cudizlcbxd (szukvnlndx ) View more | ||||||
Phase 1 | 20 | cmcemaykgp(kqaykssmwh) = rvqhklhfmi suzlmrtclq (ylznoubghc ) View more | Positive | 03 Jul 2019 | |||
Phase 1 | 41 | rlajkqzbwi(nsjakoawun) = 1patient NSCLC aklpsgobdu (kuvmcgspkk ) View more | Positive | 01 Feb 2018 | |||
Phase 1 | - | 41 | aimwuodguo(ifkxppkakj) = reduced as sign of redistribution fqrlkctgle (cwtjitolau ) View more | - | 20 May 2013 | ||
Not Applicable | 34 | Bevacizumab-based regimen (BBR) | trifodfkkj(loiyqosofz) = hnqaovfqyq cwjfnkmjhm (rbjjgqfgmt ) View more | Positive | 01 Feb 2011 | ||
trifodfkkj(loiyqosofz) = ivvyuygnjc cwjfnkmjhm (rbjjgqfgmt ) View more |